Imcyse Sa Is A Clinical Stage Biopharmaceutical Company Based In Lia Gebelgiumfounded In 2011 As A Spin Off From The Catholic University Of Leuvenimcyse Specializes In Developing Active Specific Immunotherapies For Severe Autoimmune Diseasesthe Company Employs A Team Of 11 To 50 Staff And Is Dedicated To Creating Treatments That Target The Underlying Causes Of Chronic Autoimmune Conditions The Company S Proprietary Imotopea C Technology Utilizes Modified Synthetic Peptides To Generate Cytolytic Cd4 T Cellsthese Cells Are Designed To Selectively Eliminate Harmful Immune Cells While Preserving Overall Immune Functionimcyse S Lead Candidateimcy 0098Is Currently In Phase 2 Clinical Trials For Early Onset Type 1 Diabetesshowing Promising Results In Halting Disease Progressionthe Company Also Has Programs Targeting Multiple Sclerosis And Other Autoimmune Diseasessupported By A Collaboration With Pfizer To Develop Therapies For Rheumatoid Arthritisimcyse S Focus On Disease Modification Aims To Cure Conditions Rather Than Just Manage Symptomspositioning It As A Potential Leader In Immunotherapy For Autoimmune Diseases
